Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Precision BioSciences publishes data from in vivo gene editing program » 07:16
05/18/22
05/18
07:16
05/18/22
07:16
DTIL

Precision BioSciences

$1.88 /

+0.12 (+6.82%)

, GILD

Gilead

$63.16 /

+0.91 (+1.46%)

Precision BioSciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$63.16 /

+0.91 (+1.46%)

DTIL Precision BioSciences
$1.88 /

+0.12 (+6.82%)

DTIL Precision BioSciences
$1.88 /

+0.12 (+6.82%)

12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
GILD Gilead
$63.16 /

+0.91 (+1.46%)

05/17/22 BMO Capital
Scholar Rock price target lowered to $55 from $74 at BMO Capital
05/16/22 Piper Sandler
Gilead price target lowered to $69 from $73 at Piper Sandler
04/29/22 Piper Sandler
Gilead price target raised to $73 from $72 at Piper Sandler
04/12/22 Piper Sandler
Gilead price target raised to $72 from $71 at Piper Sandler
GILD Gilead
$63.16 /

+0.91 (+1.46%)

DTIL Precision BioSciences
$1.88 /

+0.12 (+6.82%)

GILD Gilead
$63.16 /

+0.91 (+1.46%)

GILD Gilead
$63.16 /

+0.91 (+1.46%)

GILD Gilead
$63.16 /

+0.91 (+1.46%)

Yesterday
Hot Stocks
Pfizer, BioNTech receive FDA emergency use authorization for child booster » 11:44
05/17/22
05/17
11:44
05/17/22
11:44
PFE

Pfizer

$51.32 /

+0.64 (+1.26%)

, BNTX

BioNTech

$159.20 /

+7.99 (+5.28%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced the Food and Drug Administration expanded emergency use authorization to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children five through 11 years of age. The booster dose is given at least five months after the second dose of the two-dose primary series and is the same 10-microgram dose of the Pfizer-BioNTech COVID-19 Vaccine. The companies have already submitted an application to the European Medicines Agency for a booster dose in this age group and are planning to file with other regulatory agencies around the world.

ShowHide Related Items >><<
PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

Hot Stocks
FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old » 10:16
05/17/22
05/17
10:16
05/17/22
10:16
PFE

Pfizer

$50.69 /

+0.01 (+0.02%)

, BNTX

BioNTech

$156.13 /

+4.92 (+3.25%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer (PFE) BioNTech (BNTX) COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said, "Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations. The FDA has determined that the known and potential benefits of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups." Reference Link

ShowHide Related Items >><<
PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

Recommendations
Scholar Rock price target lowered to $55 from $74 at BMO Capital » 09:32
05/17/22
05/17
09:32
05/17/22
09:32
SRRK

Scholar Rock

$5.20 /

-0.36 (-6.47%)

, GILD

Gilead

$62.25 /

-0.15 (-0.24%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman lowered the firm's price target on Scholar Rock (SRRK) to $55 from $74 but keeps an Outperform rating on the shares. The company's Q1 results were better-than-expected on lower operating expenditure, while collaboration with Gilead (GILD) concluded and final collaborative revenue was recognized, the analyst tells investors in a research note. Nachman adds that his reduced price target reflects additional conservatism on timelines while also incorporating lower spending from restructuring.

ShowHide Related Items >><<
SRRK Scholar Rock
$5.20 /

-0.36 (-6.47%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

SRRK Scholar Rock
$5.20 /

-0.36 (-6.47%)

05/16/22 Piper Sandler
Scholar Rock price target lowered to $28 from $56 at Piper Sandler
03/23/22 H.C. Wainwright
Scholar Rock initiated with a Buy at H.C. Wainwright
12/22/21 Jefferies
Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
12/22/21 Jefferies
Scholar Rock downgraded to Hold from Buy at Jefferies
GILD Gilead
$62.25 /

-0.15 (-0.24%)

05/16/22 Piper Sandler
Gilead price target lowered to $69 from $73 at Piper Sandler
04/29/22 Piper Sandler
Gilead price target raised to $73 from $72 at Piper Sandler
04/12/22 Piper Sandler
Gilead price target raised to $72 from $71 at Piper Sandler
04/04/22 Piper Sandler
Gilead price target lowered to $71 from $77 at Piper Sandler
SRRK Scholar Rock
$5.20 /

-0.36 (-6.47%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

Hot Stocks
Xilio Therapeutics appoints Davis as CBO » 07:38
05/17/22
05/17
07:38
05/17/22
07:38
XLO

Xilio Therapeutics

$3.06 /

-0.31 (-9.20%)

, NVS

Novartis

$87.77 /

+1.95 (+2.27%)

Xilio Therapeutics (XLO)…

Xilio Therapeutics (XLO) announced that Stacey Davis has been appointed as chief business officer, CBO, to further the company's corporate and business development strategy that will be central to its next stage of growth. Davis brings 25 years of experience in entrepreneurial roles building teams and leading corporate and portfolio strategy. She joins Xilio from Novartis Oncology (NVS), and most recently served as vice president, lung and immuno-oncology franchise, U.S. Oncology.

ShowHide Related Items >><<
XLO Xilio Therapeutics
$3.06 /

-0.31 (-9.20%)

NVS Novartis
$87.77 /

+1.95 (+2.27%)

XLO Xilio Therapeutics
$3.06 /

-0.31 (-9.20%)

03/14/22 H.C. Wainwright
H.C. Wainwright sees little readthrough for Xilio from Nektar failure
01/10/22 H.C. Wainwright
Xilio Therapeutics initiated with a Buy at H.C. Wainwright
11/16/21 Morgan Stanley
Xilio Therapeutics initiated with an Overweight at Morgan Stanley
11/16/21 Raymond James
Xilio Therapeutics initiated with an Outperform at Raymond James
NVS Novartis
$87.77 /

+1.95 (+2.27%)

05/13/22 Piper Sandler
Point Biopharma price target lowered to $14 from $17 at Piper Sandler
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
05/09/22 Wolfe Research
Novartis downgraded to Peer Perform from Outperform at Wolfe Research
05/06/22 Morgan Stanley
Novartis price target raised to CHF 94 from CHF 90 at Morgan Stanley
XLO Xilio Therapeutics
$3.06 /

-0.31 (-9.20%)

NVS Novartis
$87.77 /

+1.95 (+2.27%)

  • 22
    Oct
NVS Novartis
$87.77 /

+1.95 (+2.27%)

NVS Novartis
$87.77 /

+1.95 (+2.27%)

Hot Stocks
Talaris Therapeutics annouces changes to board of directors » 07:24
05/17/22
05/17
07:24
05/17/22
07:24
TALS

Talaris Therapeutics

$6.65 /

+0.38 (+6.06%)

, SGMO

Sangamo

$3.88 /

-0.14 (-3.48%)

, ATRS

Antares Pharma

$5.58 /

+ (+0.00%)

Talaris Therapeutics…

Talaris Therapeutics (TALS) announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. Dr. Smith currently serves as the Chief Medical Officer at Novosteo and as a member of the Board of Directors of Sangamo Therapeutics (SGMO), Capstan Therapeutics and Antares Pharma (ATRS). Talaris also announced that Nicholas Galakatos, Ph.D., has retired from its Board.

ShowHide Related Items >><<
TALS Talaris Therapeutics
$6.65 /

+0.38 (+6.06%)

SGMO Sangamo
$3.88 /

-0.14 (-3.48%)

ATRS Antares Pharma
$5.58 /

+ (+0.00%)

TALS Talaris Therapeutics
$6.65 /

+0.38 (+6.06%)

06/01/21 SVB Leerink
Talaris Therapeutics initiated with an Outperform at SVB Leerink
06/01/21 Evercore ISI
Evercore starts Talaris Therapeutics at Outperform with $35 price target
06/01/21 Evercore ISI
Talaris Therapeutics initiated with an Outperform at Evercore ISI
06/01/21 Guggenheim
Talaris Therapeutics initiated with a Buy at Guggenheim
SGMO Sangamo
$3.88 /

-0.14 (-3.48%)

05/03/22 RBC Capital
Clinical hold being lifted a 'clear positive' for Sangamo, says RBC Capital
04/05/22 Truist
Sangamo price target lowered to $19 from $23 at Truist
01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
ATRS Antares Pharma
$5.58 /

+ (+0.00%)

04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Ladenburg
Antares Pharma downgraded to Neutral from Buy at Ladenburg
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
04/14/22 Piper Sandler
Antares Pharma downgraded to Neutral from Overweight at Piper Sandler
SGMO Sangamo
$3.88 /

-0.14 (-3.48%)

ATRS Antares Pharma
$5.58 /

+ (+0.00%)

SGMO Sangamo
$3.88 /

-0.14 (-3.48%)

ATRS Antares Pharma
$5.58 /

+ (+0.00%)

Monday
Recommendations
Gilead price target lowered to $69 from $73 at Piper Sandler » 19:00
05/16/22
05/16
19:00
05/16/22
19:00
GILD

Gilead

$62.25 /

-0.15 (-0.24%)

Piper Sandler analyst Do…

Piper Sandler analyst Do Kim lowered the firm's price target on Gilead to $69 from $73 and keeps a Neutral rating on the shares. The analyst updates his model after the company announced that the FDA lifted clinical hold on injectable enacapavir, allowing clinical study activity in HIV treatment and PrEP to resume. Kim adds that he expects pipeline studies to resume in next few weeks, pending manufacturing of new vials and delivery to trial sites, stating that he sees the long-term opportunity of lenacapavir remaining intact.

ShowHide Related Items >><<
GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

04/29/22 Piper Sandler
Gilead price target raised to $73 from $72 at Piper Sandler
04/12/22 Piper Sandler
Gilead price target raised to $72 from $71 at Piper Sandler
04/04/22 Piper Sandler
Gilead price target lowered to $71 from $77 at Piper Sandler
03/22/22 Wells Fargo
Gilead price target lowered to $63 from $70 at Wells Fargo
GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

GILD Gilead
$62.25 /

-0.15 (-0.24%)

Conference/Events
Pfizer management to meet with Oppenheimer » 16:55
05/16/22
05/16
16:55
05/16/22
16:55
PFE

Pfizer

$50.68 /

+0.78 (+1.56%)

Meeting to be held in New…

Meeting to be held in New York on May 19 hosted by Oppenheimer.

ShowHide Related Items >><<
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

Hot Stocks
Mirati Therapeutics appoints Laurie Stelzer as CFO » 16:33
05/16/22
05/16
16:33
05/16/22
16:33
MRTX

Mirati Therapeutics

$56.42 /

-0.36 (-0.63%)

, PFE

Pfizer

$50.68 /

+0.78 (+1.56%)

, TAK

Takeda Pharmaceutical

$14.27 /

-0.085 (-0.59%)

Mirati Therapeutics…

Mirati Therapeutics (MRTX) the appointment of Laurie Stelzer as the Company's CFO effective May 16. Laurie will report to the Company's CEO, David Meek. Laurie joins the Company most recently from Arena Pharmaceuticals, acquired by Pfizer (PFE), where she served as Executive Vice President and CFO since 2020. She brings 25 years of biopharma industry experience to her role in leading the company's finance functions. Prior to joining Arena, Laurie was the CFO at Halozyme Therapeutics where she led the finance, information technology, business development, project management and site operations organizations. Prior to joining Halozyme, Laurie held senior management roles at Shire, acquired by Takeda (TAK), including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division, and Head of Investor Relations. Previously she held positions of increasing responsibility during her fifteen-year career at Amgen, spanning the areas of finance, treasury, global accounting, and international/emerging markets.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
05/05/22 Citi
Mirati Therapeutics price target lowered to $208 from $227 at Citi
03/02/22 Citi
Mirati Therapeutics price target lowered to $227 from $244 at Citi
03/01/22 BMO Capital
Mirati Therapeutics price target lowered to $130 from $187 at BMO Capital
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
03/31/22 Canaccord
Canaccord starts Morphic at Buy, sees potential to take share from Takeda
02/11/22 BTIG
Protagonist Therapeutics initiated with a Buy at BTIG
02/11/22 BTIG
Morphic initiated with a Buy at BTIG
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

  • 11
    Nov
TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

Hot Stocks
Gilead says FDA lifts clinical hold on investigational lenacapavir » 16:14
05/16/22
05/16
16:14
05/16/22
16:14
GILD

Gilead

$62.19 /

-0.21 (-0.34%)

Bilead Sciences announced…

Bilead Sciences announced the U.S. Food and Drug Administration has lifted the clinical hold placed on the company's Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clinical hold following the agency's review of Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Following today's decision from the FDA, all activity can resume in the clinical studies evaluating injectable lenacapavir for HIV treatment and HIV PrEP. During the clinical hold, screening and enrollment of study participants and the dosing of injectable lenacapavir were not permitted across all lenacapavir studies. Other study activities, including the monitoring of participants, the dosing of participants in comparator arms, and the dosing of oral formulations of lenacapavir continued according to the relevant study protocol. Gilead will now work with study site investigators to fully resume the lenacapavir clinical development programs as quickly as possible.

ShowHide Related Items >><<
GILD Gilead
$62.19 /

-0.21 (-0.34%)

GILD Gilead
$62.19 /

-0.21 (-0.34%)

04/29/22 Piper Sandler
Gilead price target raised to $73 from $72 at Piper Sandler
04/12/22 Piper Sandler
Gilead price target raised to $72 from $71 at Piper Sandler
04/04/22 Piper Sandler
Gilead price target lowered to $71 from $77 at Piper Sandler
03/22/22 Wells Fargo
Gilead price target lowered to $63 from $70 at Wells Fargo
GILD Gilead
$62.19 /

-0.21 (-0.34%)

GILD Gilead
$62.19 /

-0.21 (-0.34%)

GILD Gilead
$62.19 /

-0.21 (-0.34%)

GILD Gilead
$62.19 /

-0.21 (-0.34%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.